Summary for peptidase M10.004: matrix metallopeptidase-9

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Human EST Mouse EST Substrates Inhibitors Pharma

 

Names
MEROPS Namematrix metallopeptidase-9
Other names92 kDa gelatinase, gelatinase B, macrophage gelatinase, matrix metalloproteinase 9, MMP-9, neutrophil gelatinase, type IV collagenase, type V collagenase
Domain architecture
MEROPS Classification
Classification Clan MA >> Subclan MA(M) >> Family M10 >> Subfamily A >> M10.004
Holotypematrix metallopeptidase-9 (Homo sapiens), Uniprot accession P14780 (peptidase unit: 105-458), MERNUM MER0001085
History Identifier created: Handbook of Proteolytic Enzymes (1998) Academic Press, London.
Activity
Catalytic typeMetallo
PeplistIncluded in the Peplist with identifier PL00157
NC-IUBMBSubclass 3.4 (Peptidases) >> Sub-subclass 3.4.24 (Metalloendopeptidases) >> Peptidase 3.4.24.35
EnzymologyBRENDA database
Proteolytic eventsCutDB database (184 cleavages)
Activity statushuman: active (Bannikov et al., 2004)
mouse: active (Masure et al., 1997)
PhysiologyRole in turnover of extracellular matrix proteins.
KnockoutKnockout mice develop normally and are fertile (Itoh et al., 1999). They are resistant to a form of tail pathology that normally occurs in experimental auto-immune encephalomyelitis (Dubois et al., 1999), and have reduced lung damage in response to immunoglobulin G immune complexes (Warner et al., 2001). The deficient mice are however more susceptible to anti-glomerular basement membrane glomerulonephritis, and this is attributable to a role of gelatinase B in clearing deposits of fibrin from the glomeruli (Lelongt et al., 2001).
Pharmaceutical relevanceDrug target for prevention of pathological tissue damage. Work with knock-out mouse indicates that the enzyme plays a key role in the development of airway inflammation after allergen exposure (Cataldo et al., 2002), and may also be an attractive therapeutic target for limiting the effects of pathological arterial remodeling in restenosis and atherosclerosis (Galis et al., 2002). It is also suggested that adenovirus-mediated delivery of the gene in the antisense orientation has therapeutic potential for treating gliomas (Lakka et al., 2002).
Pathways KEGGBladder cancer
KEGGEstrogen signaling pathway
KEGGHepatitis B
KEGGLeukocyte transendothelial migration
KEGGMicroRNAs in cancer
KEGGPathways in cancer
KEGGProteoglycans in cancer
KEGGTNF signaling pathway
KEGGTranscriptional misregulation in cancer
Other databases WIKIPEDIAhttp://en.wikipedia.org/wiki/MMP9
Cleavage site specificity Explanations of how to interpret the following cleavage site sequence logo and specificity matrix can be found here.
Cleavage patterng/pa/-/gScissile bondl/-/g/- (based on 369 cleavages)
weblogo
Specificity matrix
 
Amino acid P4 P3 P2 P1 P1' P2' P3' P4'
Gly 119 19 38 121 14 31 129 41
Pro 15 150 37 21 10 11 8 48
Ala 31 52 54 47 33 41 58 49
Val 27 29 18 21 38 25 21 19
Leu 31 23 26 13 104 26 18 37
Ile 13 13 9 4 30 14 10 9
Met 4 1 5 4 13 6 1 5
Phe 12 8 16 12 15 16 9 13
Tyr 2 3 13 10 15 6 4 6
Trp 0 0 0 1 2 4 2 1
Ser 19 20 27 18 20 16 31 15
Thr 9 10 12 13 6 31 18 14
Cys 1 1 4 2 0 3 4 2
Asn 10 4 3 17 3 9 5 12
Gln 12 6 20 8 21 31 9 8
Asp 7 4 3 7 5 8 10 24
Glu 11 5 16 15 8 16 12 23
Lys 14 7 25 18 21 28 9 18
Arg 14 5 35 7 6 34 7 12
His 8 6 5 10 2 11 4 3
Human genetics
Gene symbol Locus Megabases Ensembl Entrez gene Gene Cards OMIM
MMP9 20q11.2-q13.1 ENSG00000100985 4318 MMP9 120361
Mouse genetics
Gene symbol Position Megabases Ensembl Entrez gene MGI
Mmp9 2:H1-H2 ENSMUSG00000017737 17395 MGI:97011